目的 探索以解语丹联合靳三针为基础的不同治疗方案对卒中后失语症（PSA）的治疗效果。方法 收集广州市第一人民医院神经内科、中医科PSA患者120例,随机分为解语丹组、靳三针组、联合组和对照组,每组各30例。试验组除给予常规卒中治疗外,分别给予解语丹、靳三针及解语丹联合靳三针治疗,对照组仅给予常规卒中治疗,治疗周期共12周。分别利用西方失语成套测验（WAB）、汉语失语检查量表（ABC）、副反应量表（TESS）于试验前、试验2周及12周时对患者进行评估,并进行药物安全性评价,观察解语丹联合靳三针治疗卒中后失语症的临床治疗效果。结果 经2周治疗后,试验组各组WAB中的失语指数（AQ）、操作指数（PQ）、大脑皮质指数（CQ）评分分别为68.14±7.23;67.26±7.23;69.73±6.97、15.47±3.91;15.92±6.35;18.06±7.83、66.84±7.85;65.78±6.75;70.35±6.73,均较治疗前及对照组有明显改善,比较差异有统计学意义（P<0.05）;试验组各组比较,联合组各项评分优于解语丹组和靳三针组,比较差异有统计学意义（P<0.05）;治疗12周后,试验组WAB的AQ、PQ、CQ评分分别为91.87±7.81;85.75±6.87;94.58±7.83、31.57±7.38;25.67±6.28;35.72±8.31、89.74±6.98;84.16±6.79;93.56±7.88,与治疗2周后比较,差异有统计学意义（P<0.05）。言语功能各亚项评分显示,联合组在口语表达、听理解、复述、命名等方面优于其他各组,两两比较差异有统计学（P<0.05）。试验各组在2周及12周时,TESS评分比较差异无统计学意义（P<0.05）。统计分析表明,解语丹联合靳三针治疗卒中后失语症,2周后起效12周后效果更为明显。结论 解语丹联合靳三针早期治疗PSA患者能有效提升认知功能,改善患者的言语功能,提高患者的人际交往和生活自理能力,且具有较好的安全性,无严重不良反应,可为临床治疗PSA提供一种新的方法。

Objective To compare the therapeutic effects of different treatment plans based on Jieyu Dan combined with Jin's Three Needle on aphasia patients after stroke．Methods A total of 120 patients with aphasia after stroke in the neurology and traditional Chinese medicine departments of Guangzhou First People's Hospital were collected and randomly divided into Jieyu Dan group,Jin's Three Needle group,combined group and control group,with 30 cases in each group．The treatment groups were treated with Jieyu Dan,Jin's Three Needle and Jieyu Dan combined with Jin's Three Needle respectively,in addition to conventional stroke treatment．The control group was only treated with conventional stroke treatment,with a total treatment period of 12 weeks．The Western Aphasia Battery（WAB）,Aphasia Battery of Chinese（ABC）and Treatment Emergent Symptom Scale（TESS）were used to evaluate patients before,at 2 weeks and 12 weeks of the trial,and drug safety was evaluated to observe the clinical therapeutic effect of Jieyu Dan combined with Jin's Three Needle in treating post stroke aphasia．Results After 2 weeks of treatment,the aphasia quotient（AQ）,performance quotient（PQ）,cortical quotient（CQ）scores of WAB in each group of the experimental group were 68.14±7.23,67.26±7.23,69.73±6.97;15.47±3.91,15.92±6.35,18.06±7.83;66.84±7.85,65.78±6.75,70.35±6.73,respectively,and all significantly improved compared to before treatment and the control group,with significant differences（P<0.05）．Compared with the experimental group,the combined group had better scores than the Jieyu Dan group and Jin's Three Needle group,with a statistically significant difference（P<0.05）．After 12 weeks of treatment,the AQ,PQ,and CQ scores of the experimental group's WAB were 91.87±7.81,85.75±6.87,94.58±7.83;31.57±7.38,25.67±6.28,35.72±8.31;89.74±6.98,84.16±6.79,93.56±7.88,respectively．Compared with 2 weeks of treatment,the difference was statistically significant（P<0.05）．The scores of each sub item of speech function showed that the combined group was significantly better than the other groups in terms of oral expression,listening comprehension,retelling,naming,etc．,with statistical significance（P<0.05）．At 2 and 12 weeks,there were no significant statistical differences in TESS scores among the experimental groups（P<0.05）．Statistical analysis showed that the combination of Jieyu Dan and Jin's Three Needle in the treatment of post-stroke aphasia had a more significant effect after 2 weeks and 12 weeks．Conclusions The combination of Jieyu Dan and Jin's Three Needle can effectively improve cognitive function and enhance patients' self-care ability in the early treatment of aphasia after stroke．The clinical efficacy is significant and has good safety,making it an effective treatment plan for aphasia after stroke．

目的 探讨选择输尿管软镜下钬激光碎石术治疗肾结石（直径≤3 cm）的效果。方法 回顾性选择2021年1月—2023年1月广州市增城区新塘医院接收的180例肾结石（直径≤3 cm）患者为研究对象,按照手术方式分为对照组（n=90,给予经皮肾镜碎石术治疗）与观察组（n=90,给予输尿管软镜下钬激光碎石术治疗）,比较两组的结石清除效果、并发症、手术治疗情况、炎症反应、肾功能指标。结果 观察组结石清除89例、清除率98.89%,与对照组85例、清除率94.44%比较差异无统计学意义（χ²=2.758,P=0.096）;观察组发生并发症1例、发生率1.11%,比对照组8例、发生率8.89%更低（χ²=5.731,P=0.016）。与对照组（58.45±10.62）min、（32.26±4.49）mL、（10.42±2.27）g/L、（4.25±0.86）min比较,观察组手术操作时长（70.05±15.24）min更高,术中失血量（10.22±2.28）mL更少、术后血红蛋白（Hb）下降值（3.94±1.05）g/L更低,视觉模拟评分法（VAS）（2.22±0.42）分更低（t分别为5.924、41.521、24.579、20.121,P<0.05）。术后两组白细胞计数（WBC）、C-反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、降钙素原（PCT）明显升高,而观察组（7.62±1.15）×10⁹/L、（14.25±2.24）mg/L、（1.65±0.34）mg/mL、（17.22±1.45）ng/ml明显低于对照组（8.82±1.41）×10⁹/L、（22.26±3.63）mg/L、（2.56±0.44）mg/mL、（20.64±2.87）ng/mL（t分别为6.256、17.814、15.525,10.090,P<0.05）。术后两组各指标明显升高,血肌酐（Scr）、胱抑素-C（Cys-C）、血尿素氮（BUN）组间比较差异无统计学意义（P>0.05）;而观察组、中性粒细胞明胶酶相关脂质运载蛋白（NGAL）（4.95±0.84）μg/L明显低于对照组（6.45±1.15）μg/L（t=9.992,P<0.05）。结论 输尿管软镜引导下置入钬激光进行碎石可有效治疗直径≤3 cm肾结石,取得与经皮肾镜相当的疗效,可进一步减轻疼痛,减少出血,控制炎症反应,避免肾功能损伤,安全性更高。

目的 探究纤维桩联合复合树脂及氧化锆烤瓷冠修复治疗根管治疗（RCT）后后牙楔状缺损（WSD）的效果。方法 选取2019年8月—2022年8月在新乡市口腔医院治疗的300例（300牙）RCT后后牙WSD患者,按随机数字表法分成A组（n=150）、B组（n=150）。A组接受纤维桩联合复合树脂及氧化锆烤瓷冠修复治疗,B组接受金属烤瓷冠（PFM）联合金属桩核（MPC）修复治疗。对比2组修复成功率、修复效果、修复前后牙周健康指标[牙龈指数（GI）、菌斑指数（PLI）、牙周探诊深度（PD）]、龈沟液炎性因子[白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）]水平。结果 A组修复成功率为97.33%（146/150）,高于B组的87.33%（131/150）（P<0.05）;A组边缘密合性、表面质地、颜色匹配均优于B组（P<0.05）;修复6个月后A组GI、PLI、PD较B组低（P<0.05）;修复1个月后A组龈沟液TNF-α、IL-6水平较B组低,IL-10水平较B组高（P<0.05）。结论 与PFM联合MPC修复治疗RCT后后牙WSD患者相比,应用纤维桩联合复合树脂及氧化锆烤瓷冠修复治疗更有助于提升修复成功率及修复效果,改善牙周健康,且对组织产生创伤更小。

Objective To investigate the restorations outcome of fibre post + composite resin + zirconia porcelain crown for patients with wedge-shaped defects（WSD）in posterior teeth after root canal therapy（RCT）．Methods A total of 300 patients（300 teeth）with posterior WSD after RCT in our hospital（from August 2019 to August 2022）were selected and divided into group A（n=150）and group B（n=150）according to random number table method．Group A received composite resin + zirconia porcelain crown + fiber post repair treatment,while group B received porcelain fused to metal（PFM）+ metal post core（MPC）repair treatment．The success rate of repair,the effect of repair,the periodontal health indicators before and after repair[gingival index（GI）,plaque index（PLI）,periodontal probing depth（PD）],and the levels of gingival creval fluid inflammatory factors[interleukin-6（IL-6）,IL-10,tumor necrosis factor-α（TNF-α）] were compared between the two groups．Results The success rate of repair in group A was 97.33%（146/150）,higher than 87.33%（131/150）of group B（P<0.05）．The edge tightness,surface texture and color matching of group A were better than those of group B（P<0.05）．After 6 months of repair,GI,PLI and PD in group A were lower than those in group B（P<0.05）．After one month of repair,the contents of TNF-α and IL-6 in gingival crevicular fluid of group A were lower than those of group B,and the contents of IL-10 were higher than those of group B（P<0.05）．Conclusions Compared with PFM+MPC in the treatment of posterior WSD patients after RCT,the application of composite resin + zirconia porcelain crown + fiber post repair is more helpful to improve the success rate and effect of repair,improve periodontal health,and cause less tissue trauma．

脑卒中是临床常见的急性脑血管疾病,常有偏瘫、肩手综合征、下肢深静脉血栓等后遗症,严重影响患者的生活质量。温针疗法是中医传统的特色疗法,近年来,应用以温针为主的相关疗法治疗脑卒中后遗症的报道越来越多,在临床上得到广泛应用。本文归纳分析了近10年来温针疗法治疗脑卒中后肩手综合征、偏瘫、下肢深静脉血栓三大主要疾病的案例及研究,以期为相关研究与应用提供参考。

Stroke is a common acute cerebrovascular disease in clinical practice,which frequently leaves sequelae like hemiplegia,shoulder-hand syndrome and deep vein thrombosis of the lower extremities,and vastly reduces the quality of life of patients．Warm needling is a characteristic therapy of traditional Chinese medicine．In recent years,there have been more and more reports of warm needling-based related therapies for the treatment of stroke sequelae,and it has been widely used in clinical practice．This article summarizes and analyzes the cases and studies of warm needing therapy in the treatment of shoulder-hand syndrome,hemiplegia and deep vein thrombosis of the lower extremities after stroke in the past 10 years,so as to provide reference for related research and application．

血友病是一种由于X染色体上凝血因子基因突变所致的遗传性出血性疾病,目前主要的治疗方法是凝血因子替代疗法。但长期频繁的注射用药往往导致患者依从性差,容易产生抑制性抗体,从而影响治疗效果。虽然现在延长半衰期的新型凝血因子药物、人源化双特异性抗体以及抗组织因子途径抑制剂单克隆抗体等用于疾病治疗,在给药方式和作用持续时间上已有很大进步,但它们仍无法治愈血友病。因此,以疾病根治为重要目标的基因治疗被设计出来,近年来受到了广泛的关注。该文介绍了血友病基因治疗的原理、基因治疗载体的选择、基因治疗预处理方案,总结了现阶段基因治疗临床应用的安全性和有效性;最后讨论基因治疗目前存在的问题以及未来发展方向。

Hemophilia is a genetic bleeding disorder resulting from mutations in coagulation factor genes on the X chromosome．The mainstay of current treatment is coagulation factor replacement therapy．However,frequent and long-term injections often lead to poor patient compliance,easy inhibitor development,and compromised therapeutic efficacy．Despite advancements in delivery methods and prolonged action of novel agents such as extended half-life coagulation factor concentrates,humanized bispecific antibodies,and anti-tissue factor pathway inhibitor monoclonal antibodies,these approaches still fall short of curing hemophilia．Consequently,gene therapy,aiming for disease eradication,has garnered significant attention in recent years．This review delves into the principles of gene therapy,the selection of gene therapy vectors,and gene therapy preconditioning regimens．It summarizes the safety and efficacy of gene therapy in current clinical applications and discusses challenges and future directions in this field．

目的 探讨富血小板血浆（PRP）联合关节镜治疗Ⅲ度半月板损伤患者的临床疗效,及其对膝关节功能恢复时间的影响。方法 选取2021年2月—2022年2月南方医科大学南方医院增城院区骨科收治的Ⅲ度半月板损伤患者45例,采用随机数字法分为观察组22例与对照组23例,对照组患者在关节镜下行半月板成形术,观察组在对照组基础上给予PRP治疗。观察两组患者术后恢复时间、治疗效果及并发症发生情况;比较两组治疗前和治疗后1、3、6个月膝关节功能、疼痛情况。结果 利用观察组患者自体全血制备的PRP,其血小板的回收率、红细胞留存率、白细胞留存率分别为（91.00±9.27）%、（0.29±0.12）%、（29.98±6.68）%,PRP制备质量稳定、可控。观察组联合PRP治疗术与关节镜手术治疗后恢复时间均短于对照组,观察组治疗有效率高于对照组（P<0.05）。经重复方差测量分析,两组美国特种外科医院膝关节评分系统（HSS）评分、西安大略大学和麦克马斯特大学骨关节炎指数（WOMAC）评分、视觉模拟疼痛评分法（VAS）交互（F_交互=1.869、F_交互=1.482、F_交互=2.193）比较差异均有统计学意义（P<0.05）;与对照组治疗后1、3、6个月比较,观察组HSS评分升高,WOMAC评分、VAS评分下降（P<0.05）;观察组并发症总发生率4.55%低于对照组30.43%（χ²=5.156、P=0.023）。结论 对于Ⅲ度半月板损伤患者,采用PRP联合关节镜手术治疗可帮助患者消炎止痛、加快疗效、加快膝关节功能的恢复,缩短其恢复的时间,效果良好,且安全性较高。

Objective To investigate the clinical effect of platelet rich plasma（PRP）combined with arthroscopy treatment on patients with third degree meniscus injury,and its impact on the recovery time of knee joint function．Methods From February 2021 to February 2022,45 patients with III-degree meniscal injuries admitted to the Department of Orthopedics,Zengcheng district,Nanfang Hospital of Southern Medical University were selected and divided into an observation group of 22 cases and a control group of 23 cases using the random number method．Patients in the control group received menisplasty under arthroscopy,and the observation group was given PRP treatment on the basis of the control group．The postoperative recovery time,treatment effects and complications of the two groups of patients were observed;the knee joint function and pain of the two groups before treatment and 1,3,and 6 months after treatment were compared．Results The platelet recovery rate,red blood cell retention rate,and white blood cell retention rate of PRP prepared from the autologous whole blood of patients in the observation group were（91.00±9.27）%,（0.29±0.12）%,and（29.98±6.68）% respectively．The PRP preparation quality is stable and controllable．The recovery time after combined PRP treatment and arthroscopic surgery in the observation group was shorter than that in the control group,and the treatment effectiveness of the observation group was higher than that of the control group（P<0.05）．After repeated measures of variance analysis,the comparison of American Hospital for Special Surgery（HSS）Knee Scoring System,Western Ontario and McMaster Universities Osteoarthritis Index（WOMAC）,and visual analogue pain scales（VAS）interacted(F_Interaction=1.869,F_interaction=1.482,F_interaction=2.193),the differences were statistically significant（P<0.05）．Compared with the control group 1,3,and 6 months after treatment,the HSS score of the observation group increased,and the WOMAC score,VAS score decreased（P<0.05）;the total incidence of complications in the observation group was 4.55%,lower than that in the control group（30.43%,χ²=5.156,P=0.023）．Conclusions For patients with III-degree meniscal injuries,PRP combined with arthroscopic surgery can help reduce inflammation and pain,speed up the curative effect,accelerate the recovery of knee joint function,and shorten the recovery time．It has good effects and is relatively safe．

目的 分析恩格列净对2型心肾综合征（CRS）患者的治疗效果。方法 研究于2021年10月—2023年10月进行,随机抽取88例2型CRS患者,经计算机程序随机分成对照组（44例,给予常规治疗）、实验组（44例,在常规治疗的同时加用恩格列净）,通过对比两组患者心、肾功能指标来评估疗效,并记录两组患者治疗过程中发生的不良反应。结果 治疗后,实验组LAD、LVED低于对照组,而LVEF高于对照组;实验组血清肌酐、尿酸等肾功能指标水平均低于对照组（均P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论 对于2型CRS患者,恩格列净可促进其心、肾功能的改善,且无过多不良反应,安全性理想,治疗效果可观,值得推广。

Objective To analyze the therapeutic effect of empagliflozin on patients with type 2 cardiorenal syndrome（CRS）．Methods The study was conducted from October 2021 to October 2023,and 88 patients with type 2 CRS were randomly selected and divided into control group（44 cases,receiving conventional treatment）and experimental group（44 cases,receiving conventional treatment combined with englaglitzin）by computer program．The efficacy was evaluated by comparing cardiac and renal function indexes and adverse reactions．Results After treatment,the LAD and LVED of the experimental group were lower than those of the control group,while LVEF was higher than that of the control group．The levels of serum creatinine,uric acid and other renal function indexes in the experimental group were lower than those in the control group after treatment（P<0.05）．There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）．Conclusions For patients with type 2 CRS,empagliflozin can promote the improvement of cardiac and renal function without many side effects,with ideal safety and considerable therapeutic effect,which is worthy of promotion．

本文探讨临床药师对口服靶向药物的非小细胞肺癌患者开展药学服务的要点,以案例为依据,通过查阅药品说明书、指南及文献等,分析药学服务的内容和方向。临床药师在安全性评估、剂量调整、个体化治疗方案选择、用药教育和健康宣教等方面为患者和临床医生提供专业、全面的药学服务。临床药师通过全程参与患者的治疗过程,指导患者正确用药、优化治疗方案,利用专业优势解决临床实际问题,提升药学服务质量的同时体现了药师的职业价值。

To explore the key points of pharmaceutical care for non-small cell lung cancer patients with oral targeted drugs．Based on clinical cases,the content and direction of pharmaceutical care were analyzed with drug instructions,guidelines and literature．Clinical pharmacists provided professional and comprehensive pharmaceutical services for patients and clinicians in safety assessment,dose adjustment,individualized treatment plan selection,medication education and health education．Clinical pharmacists participate in the whole treatment process,guide patients to use drugs correctly,optimize treatment plans,use professional advantages to solve clinical practical problems,improve the quality of pharmaceutical care and reflect the professional value of pharmacists．

目的 分析国产帕利哌酮缓释片治疗稳定期精神分裂症的疗效与安全性。方法 采用随机数字表法将驻马店市第二人民医院2021年10月—2023年10月收治的108例稳定期精神分裂症患者分为对照组（服用原研帕利哌酮缓释片）与观察组（服用国产帕利哌酮缓释片）,每组各54例,以阳性与阴性症状量表（PANSS）评分变化为疗效衡量指标,以不良反应发生率及药物副反应量表（TESS）评分变化为安全性衡量指标。结果 治疗后,两组PANSS评分均比治疗前降低,组内不同时间点评分差异有统计学意义（t=22.147、4.513、3.431、21.369、3.927、3.601,P值分别为<0.001、<0.001、0.001、<0.001、<0.001、<0.001）,但组间不同时间点评分比较差异无统计学意义（t=0.281、0.043、0.150,P=0.779、0.966、0.881）;观察组不良反应发生率（14.81%）与对照组（12.96%）比较差异无统计学意义（χ²=0.090,P=0.765）;两组TESS评分接近,不良反应皆轻微（t=0.185,P=0.856）。结论 国产帕利哌酮缓释片治疗稳定期精神分裂症患者可促进症状改善,且不良反应轻微,疗效及安全性与原研制剂相当。

Objective To analyze the efficacy and safety of domestic paliperidone sustained-release tablets in the treatment of stable schizophrenia．Methods A total of 108 patients with stable schizophrenia admitted to Zhumadian Second People's Hospital from October 2021 to October 2023 were divided into control group（taking the original paliperidone sustained-release tablet）and observation group（taking domestic paliperidone sustained-release tablet）by random number table method,with 54 cases in each group．The change of Positive and Negative Symptom Scale（PANSS）was used as the efficacy measure,and the change of incidence of adverse reactions and Treatment Emergent Symptom Scale（TESS） score was used as the safety measure．Results After treatment,PANSS scores in both groups were lower than before treatment,and the differences in scores at different time points in the groups were statistically significant（t=22.147,4.513,3.431,21.369,3.927,3.601,the P values were<0.001,<0.001,0.001,<0.001,<0.001,<0.001,respectively）．However,there was no significant difference in scores at different time points between the groups（t=0.281,0.043,0.150,P=0.779,0.966,0.881）．There was no significant difference in the incidence of adverse reactions between observation group（14.81%）and control group（12.96%）（χ²=0.090,P=0.765）．TESS scores were similar between the two groups,and adverse reactions were mild（t=0.185,P=0.856）．Conclusions The domestic paliperidone sustained-release tablets can improve the symptoms of stable schizophrenia patients,and the side effects are slight,and the efficacy and safety are comparable to the original agent．

目的 探讨清热化痰宣肺汤治疗痰热壅肺型重症肺炎的临床效果。方法 选择2022年3月—2023年6月天津市中西医结合医院收治的158例痰热壅肺型重症肺炎患者进行探讨,采用随机分组法分为研究组和对照组,每组各79例,对照组接受常规对症处理联合抗生素治疗,研究组在对照组基础上给予清热化痰宣肺汤,两组均治疗2周,比较疗效、中医证候积分、肺功能、血气分析结果以及不良反应发生情况。结果 研究组总有效率为94.94%,高于对照组的84.81（P=0.035）;研究组治疗后发热、痰壅以及气促评分分别为（1.12±0.33）分、（1.02±0.28）分及（1.16±0.30）分;对照组治疗后发热、痰壅以及气促评分分别为（1.45±0.36）分、（2.11±0.42）分及（2.06±0.39）分,研究组和对照组各项评分均较治疗前降低（均P<0.05）,研究组低于对照组（P均<0.05）;治疗后研究组PEF、FEV₁、FVC以及MVV分别为（3.48±0.53）L/s、（2.95±0.52）L、（2.98±0.58）L、（88.15±5.25）L/min,治疗后对照组的PEF、FEV₁、FVC以及MVV分别为（4.22±0.53）L/s、（2.41±0.47）L、（2.98±0.58）L、（88.15±5.25）L/min,两组均较治疗前升高（均P<0.05）,且研究组高于对照组（均P<0.05）; 治疗后研究组和对照组PaO₂分别为（9.77±1.12）kPa、（9.33±1.09）kPa,均较治疗前升高（均P<0.05）,研究组高于对照组（P=0.013）,治疗后研究组和对照组的PaCO₂分别为（4.22±0.14）kPa、（5.11±0.16）kPa,均较治疗前下降（均P<0.05）,研究组低于对照组（P<0.001）;研究组出现3例恶心不良反应,对照组未见不良反应发生,组间无显著差异（P>0.05）。结论 清热化痰宣肺汤治疗痰热壅肺型重症肺炎效果理想,可明显改善肺功能及血气指标,且具有较高安全性。